These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19474412)

  • 1. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.
    Cysique LA; Vaida F; Letendre S; Gibson S; Cherner M; Woods SP; McCutchan JA; Heaton RK; Ellis RJ
    Neurology; 2009 Aug; 73(5):342-8. PubMed ID: 19474412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-associated brain dysfunction in the era of HAART: reasons for hope, but continued concern.
    Cohen RA; Gongvatana A
    Neurology; 2009 Aug; 73(5):338-9. PubMed ID: 19553591
    [No Abstract]   [Full Text] [Related]  

  • 3. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.
    Sacktor N; Nakasujja N; Skolasky RL; Robertson K; Musisi S; Ronald A; Katabira E; Clifford DB
    Neurology; 2009 Jan; 72(2):165-70. PubMed ID: 19139369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
    Ndhlovu LC; Umaki T; Chew GM; Chow DC; Agsalda M; Kallianpur KJ; Paul R; Zhang G; Ho E; Hanks N; Nakamoto B; Shiramizu BT; Shikuma CM
    J Neurovirol; 2014 Dec; 20(6):571-82. PubMed ID: 25227930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
    Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
    AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
    Robertson KR; Su Z; Margolis DM; Krambrink A; Havlir DV; Evans S; Skiest DJ;
    Neurology; 2010 Apr; 74(16):1260-6. PubMed ID: 20237308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
    Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
    J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.
    Cysique LA; Brew BJ
    J Neurovirol; 2011 Apr; 17(2):176-83. PubMed ID: 21416169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors related to HIV-associated neurocognitive impairment differ with age.
    Fogel GB; Lamers SL; Levine AJ; Valdes-Sueiras M; McGrath MS; Shapshak P; Singer EJ
    J Neurovirol; 2015 Feb; 21(1):56-65. PubMed ID: 25404233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dementia and neurocognitive disorders due to HIV-1 infection.
    Ances BM; Ellis RJ
    Semin Neurol; 2007 Feb; 27(1):86-92. PubMed ID: 17226745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort.
    Robinson-Papp J; Byrd D; Mindt MR; Oden NL; Simpson DM; Morgello S;
    Arch Neurol; 2008 Aug; 65(8):1096-101. PubMed ID: 18695060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
    Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
    J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.
    Nakasujja N; Miyahara S; Evans S; Lee A; Musisi S; Katabira E; Robertson K; Ronald A; Clifford DB; Sacktor N
    Neurology; 2013 Jan; 80(2):196-202. PubMed ID: 23269596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
    Heaton RK; Clifford DB; Franklin DR; Woods SP; Ake C; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Rivera-Mindt M; Vigil OR; Taylor MJ; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I;
    Neurology; 2010 Dec; 75(23):2087-96. PubMed ID: 21135382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Brain Structure Changes and Cognitive Function With Combination Antiretroviral Therapy in HIV-Positive Individuals.
    Sanford R; Fellows LK; Ances BM; Collins DL
    JAMA Neurol; 2018 Jan; 75(1):72-79. PubMed ID: 29131878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF penetration by antiretroviral drugs.
    Eisfeld C; Reichelt D; Evers S; Husstedt I
    CNS Drugs; 2013 Jan; 27(1):31-55. PubMed ID: 23160938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
    Heseltine PN; Goodkin K; Atkinson JH; Vitiello B; Rochon J; Heaton RK; Eaton EM; Wilkie FL; Sobel E; Brown SJ; Feaster D; Schneider L; Goldschmidts WL; Stover ES
    Arch Neurol; 1998 Jan; 55(1):41-51. PubMed ID: 9443710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.
    Winston A; Stöhr W; Antinori A; Amieva H; Perré P; De Wit S; Reynes J; Gompels M; dʼArminio Monforte A; Gatell JM; Grarup J; Pozniak A; Babiker A; Raffi F; Richert L;
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):185-192. PubMed ID: 27749603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
    Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-associated neurocognitive disorders (HAND).
    Elbirt D; Mahlab-Guri K; Bezalel-Rosenberg S; Gill H; Attali M; Asher I
    Isr Med Assoc J; 2015 Jan; 17(1):54-9. PubMed ID: 25739180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.